Factorial Energy Inc. quarterly report, Q3 FY2026

Factorial Energy Inc. — Q3 2026 Form 10-Q

Reporting period: Quarter and nine months ended September 30, 2026; unaudited. Factorial develops solid-state and other advanced battery technologies and remains a development-stage company. The June 5, 2026 de-SPAC and PIPE transaction was accounted for as a reverse recapitalization.

Financial summary

Amounts below are in millions of dollars except per-share data. Comparisons are with the corresponding 2025 period.

MetricQ3 2026Nine months 2026Comparable 2025
Revenue$0.026$0.026None reported
Cost of revenue / gross loss$1.831 / $(1.805)$1.831 / $(1.805)None reported
Operating expenses$14.630$34.082$27.544 / $52.068
Operating loss$(16.435)$(35.887)$(27.544) / $(52.068)
Net income (loss)$8.840$(11.076)$(34.635) / $(58.074)
Operating cash flowNot separately clear in the filing text$(26.098)$(20.237)
  • Q3 basic and diluted earnings per share were $0.08 and $0.07; nine-month basic and diluted loss per share were $(0.19) and $(0.70). Q3 net income and nine-month earnings measures were materially affected by noncash gains from remeasuring private warrant liabilities.
  • Q3 and nine-month revenue came from the first commercial drone-cell sales. Revenue remains nominal; cost of revenue includes a $1.779 million inventory write-down to net realizable value, so the company reported a substantial gross loss.
  • Research and development expense was $4.068 million for Q3 and $12.592 million for nine months, down from $5.878 million and $19.377 million. Management cited partner reimbursements and lower facility costs. Selling, general and administrative expense rose to $6.495 million and $17.423 million, respectively, reflecting higher professional fees and, for nine months, payroll costs.
  • Q3 included a $4.067 million operating expense for an arbitration judgment; the associated accrued liability was approximately $4.5 million, including $0.4 million interest. The award was issued October 7, 2026, after quarter-end, for a dispute existing during the reporting period.

Financial position and liquidity

  • At September 30, cash and cash equivalents were $95.436 million; restricted cash was $0.888 million. Current assets were $101.974 million and current liabilities $10.398 million. Total assets were $134.252 million and total liabilities $38.843 million.
  • Nine-month operating cash use was $26.098 million; investing cash use was $3.397 million, mainly capital expenditures; financing provided $96.124 million, principally $92.0 million of net de-SPAC/PIPE proceeds. Ending cash, cash equivalents and restricted cash totaled $96.324 million.
  • The transaction raised approximately $112.1 million gross and incurred approximately $20.1 million of transaction costs. The company had $20.604 million of liability-classified private warrants at quarter-end, but no convertible promissory notes outstanding. Operating lease liabilities totaled approximately $9.595 million.
  • Management says cash on hand is expected to cover working capital and capital expenditure needs for at least 12 months from filing, and estimates runway into the first half of 2028 under its current operating plan. Management says the transaction proceeds alleviated substantial doubt about going concern, while warning that additional financing may be needed if assumptions or business conditions change.
  • 2026 capital expenditure guidance is $10 million to $12 million; $3.397 million was spent in the first nine months. Facility expansion is planned in phases through 2028, with later scaling expected primarily through manufacturing partners.

Material changes, outlook and risks

  • The de-SPAC closed June 5, 2026; preferred stock and convertible notes converted into common stock. The company reported 91,547,994 Series A and 15,512,742 Series B shares outstanding at quarter-end. Series B shares carry ten votes each; founders collectively held approximately 62.9% of voting power as of September 30.
  • Quarterly net income contrasts with continued operating losses and cash burn: the $24.012 million Q3 gain from private warrant remeasurement substantially offset operating losses. The nine-month remeasurement gain was $28.750 million. These gains are noncash and depend on valuation assumptions.
  • Factorial expects R&D and general and administrative expenses to increase as it develops products, expands production capabilities and meets public-company requirements. It has not generated substantive revenue from operations and says product costs currently exceed related revenue.
  • Key risks include technical and manufacturing scale-up, limited customer concentration and uncertain demand, supplier and raw-material availability and costs, tariffs and export controls, product safety and liability, competition, and the need for future financing. The company also cites foreign-exchange exposure and does not currently hedge it.
  • Disclosure controls and internal control over financial reporting were not effective at quarter-end because of a previously identified material weakness involving system access and segregation of duties, reconciliations, and review/documentation of transactions. Management expects remediation in 2027 and estimates approximately $0.8 million in associated costs.
  • The company identified an immaterial error in weighted-average shares used for Q2 2026 EPS: shares issued in the business combination were omitted for part of the period. The filing says prior net loss was unaffected and EPS will be revised when those periods are presented again.
  • Other notable exposures include a $0.634 million accrued private-issuance liability for 100,000 advisor shares pending authorization, and significant potential dilution from outstanding warrants, options, and registered resale shares. The filing reports no other material legal proceedings beyond the arbitration award.

Important facts for investors to verify

  • Whether drone-cell sales convert into recurring, material revenue and whether gross margins improve after the inventory write-down.
  • Cash burn, actual capital spending against the $10 million–$12 million 2026 range, and the assumptions supporting the projected runway into the first half of 2028.
  • Progress on customer and manufacturing milestones, including partner commitments, production yields, product qualification, and the planned expansion through 2028.
  • The sensitivity of reported earnings and the $20.604 million private-warrant liability to share price and valuation assumptions; the Q3 gain was noncash.
  • Payment and settlement status of the approximately $4.5 million arbitration award, and any further material legal or contractual claims.
  • Remediation and testing of the material weakness, and whether the EPS correction or subsequent reporting identifies any additional control or reporting issues.
  • Potential dilution and governance implications of warrants, options, resale-eligible shares, and founders’ voting control.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.